Clinical Trial Update: TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating umbralisib (TGR-1202) in treatment-naïve chronic lymphocytic leukemia was terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• umbralisib

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2023-03-24